ScreenerHero

PHVS Pharvaris N.V.

NAS · US · Healthcare · Biotechnology · pharvaris.com
31.68USD+1.80%Mkt Cap: 2.22B $P/E: —

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The com…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.22B USD
Enterprise Value1.87B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-175.70M USD
Revenue/Share—
Last Price31.68 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees148
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.20
PEG—
EV/EBITDA-10.25
EV/Revenue—
P/S—
P/B6.39
EPS (TTM)-3.06
EPS (Forward)-3.05
52W Range
20.6549% of range43.25
52W High43.25 USD
52W Low20.65 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-64.77%
ROA-58.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-137.07M USD
CapEx (TTM)164.62K USD
FCF Margin—
FCF Yield-4.06%
Net Debt-317.61M USD
Net Debt/EBITDA1.74
Balance Sheet
Debt/Equity0.00
Current Ratio11.94
Quick Ratio11.82
Book Value/Sh4.87 USD
Cash/Share4.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)57.48 USD
Upside (mean)+81.4%
Target Range41.21 USD – 76.44 USD
41.21+81.4% to mean76.44
# Analysts14
Ownership
Shares Out.70.20M
Float44.13M
Insiders6.14%
Institutions93.23%
Short Interest
Short Ratio1.7d
Short % Float3.09%
Short % Out.2.54%
Shares Short1.78M
Short (prev mo.)1.78M
Technical
SMA 5034.95 (-9.4%)
SMA 20030.48 (+3.9%)
Beta-2.46
S&P 52W Chg15.78%
Avg Vol (30d)895.81K
Avg Vol (10d)690.36K
Technical Indicators
RSI (14)39.0
MACD-1.2431
MACD Signal-0.8752
MACD Hist.-0.3679
BB Upper40.15 USD
BB Middle34.19 USD
BB Lower28.23 USD
BB Width34.85%
ATR (14)1.652 USD
Vol Ratio (20d)0.32x